A New Blood Test May Help Catch Kidney Problems Early in Children with Type 1 Diabetes

Diabetic kidney disease (DKD) is a serious complication that can develop silently in people with Type 1 diabetes. By the time symptoms appear, kidney damage may already be advanced. If doctors could catch it earlier, they might be able to slow or prevent progression through lifestyle changes and medication.

Currently, kidney damage is detected using tests like albumin-to-creatinine ratios and serum creatinine levels. But these methods may not catch the earliest stages of injury. Researchers are searching for more sensitive biomarkers—biological markers in blood or urine that signal trouble before traditional tests do.

A research team in Egypt compared 50 children with Type 1 diabetes (who had been diagnosed for at least 5 years) to 40 healthy children. They measured a protein called clusterin in the participants' urine using a laboratory technique called ELISA.

Children with diabetes had much higher urinary clusterin levels (49.7 pg/mL) compared to healthy children (32.3 pg/mL). Within the diabetes group, clusterin levels tracked with other markers of kidney stress and liver health, including serum creatinine and triglycerides. Interestingly, clusterin did not correlate with blood sugar control (HbA1c) or body weight, suggesting it measures something different than these factors.

Clusterin is a glycoprotein—a protein with sugar molecules attached—that appears when cells are under stress from oxidative damage. In the kidneys, oxidative stress damages the tiny tubules that filter blood and reabsorb important nutrients. When these tubules are injured, clusterin spills into the urine.

The study found that at a threshold of 37.6 pg/mL, urinary clusterin showed strong ability to distinguish between children with diabetes and healthy controls. This suggests it could become a useful screening tool.

This is early-stage research. The study was relatively small and involved children at one university hospital. Before urinary clusterin could be used in clinical practice, larger studies would be needed to confirm these findings in diverse populations, track whether clusterin levels predict kidney problems over time, and compare clusterin to other emerging biomarkers.

If future research confirms clusterin's value, it might become part of routine kidney monitoring for children and young people with Type 1 diabetes. For now, standard monitoring—regular checks of kidney function, blood pressure, and urine protein—remains the recommended approach. Talk with your healthcare team about what monitoring is right for you or your child.

Source: Journal of clinical research in pediatric endocrinology. Evidence type: PubMed indexed literature. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.